

Medical Coverage Policy | Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies



EFFECTIVE DATE: 04|01|2021
POLICY LAST UPDATED: 04|01|2021

OVERVIEW

Comprehensive genomic profiling offers the potential to evaluate a large number of genetic markers at a single time to identify cancer treatments that target specific biologic pathways. This policy focuses on “expanded” panels, which are defined as molecular panels that test a wide variety of genetic markers in cancers without regard for whether specific targeted treatment has demonstrated benefit. This approach may result in a treatment different from that usually selected for a patient based on the type and stage of cancer.

Genetic testing of circulating tumor DNA and circulating tumor cells in peripheral blood (referred to as “liquid biopsy”) potentially offers a noninvasive alternative to tissue biopsy for therapeutic decisions and prognosis in patients with cancer. For patients with non-small-cell lung cancer, the detection of “driver mutations” or resistance variants is important for selecting patients for targeted therapy.

The following tests are addressed in this policy:

- OncoPrint™ Dx Target Test (Life Technologies Corp)
- FoundationOne CDx™ (F1CDx) (Foundation Medicine)
- Guardant360® CDx (Guardant Health)
- MSK-IMPACT [Integrated Mutation Profiling of Actionable Cancer Targets] (Memorial Sloan Kettering Cancer Center)
- Praxis (TM) Extended RAS Panel (Illumina)
- myChoice® CDx (Myriad)

MEDICAL CRITERIA

Medicare Advantage Plans

The following tests will be covered when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, ordered by a treating physician and the applicable medical criteria are met:

- OncoPrint™ Dx Target Test – 0022U
- FoundationOne CDx™ (F1CDx) – 0037U
- Praxis (TM) Extended RAS Panel – 0111U
- myChoice® CDx – 0172U

Somatic (Acquired) Cancer:

1. Patient has:
 - A. either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and
 - B. not been previously tested with the same test using NGS for the same cancer genetic content, and
 - C. decided to seek further cancer treatment (e.g., therapeutic chemotherapy).
- AND
2. The diagnostic laboratory test using next generation sequencing (NGS) must have:
 - A. Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and,
 - B. an FDA-approved or -cleared indication for use in that patient’s cancer; and,

- C. results provided to the treating physician for management of the patient using a report template to specify treatment options.

OR

Germline (Inherited) Cancer:

1. Patient has:
 - A. ovarian or breast cancer; and,
 - B. a clinical indication for germline (inherited) testing for hereditary breast or ovarian cancer; and,
 - C. a risk factor for germline (inherited) breast or ovarian cancer; and
 - D. not been previously tested with the same germline test using NGS for the same germline genetic content.

AND

2. The diagnostic laboratory test using NGS must have all of the following:
 - A. FDA-approval or clearance; and,
 - B. results provided to the treating physician for management of the patient using a report template to specify treatment options.

The following test will be covered when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, ordered by a treating physician and the applicable medical criteria are met:

- **Guardant360® CDx – 0242U (Code Effective 4/1/2021. For Dates of Service prior to 4/1/2021, an Unlisted CPT code must be used.)**

Somatic (Acquired) Cancer:

1. Patient has:
 - A. either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and
 - B. not been previously tested with the same test using NGS for the same cancer genetic content, and
 - C. decided to seek further cancer treatment (e.g., therapeutic chemotherapy).

AND

2. The diagnostic laboratory test using next generation sequencing (NGS) must have:
 - A. Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and,
 - B. an FDA-approved or -cleared indication for use in that patient's cancer; and,
 - C. results provided to the treating physician for management of the patient using a report template to specify treatment options.

OR

Germline (Inherited) Cancer:

1. Patient has:
 - A. ovarian or breast cancer; and,
 - B. a clinical indication for germline (inherited) testing for hereditary breast or ovarian cancer; and,
 - C. a risk factor for germline (inherited) breast or ovarian cancer; and
 - D. not been previously tested with the same germline test using NGS for the same germline genetic content.

AND

2. The diagnostic laboratory test using NGS must have all of the following:
 - A. FDA-approval or clearance; and,
 - B. results provided to the treating physician for management of the patient using a report template to specify treatment options.

AND all of the following:

- Patient has been diagnosed with a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that did not originate from the central nervous system. Patients who would meet all of the indications

on the FDA label for larotrectinib if they are found to have an NTRK mutation may be considered to have advanced cancer, **and**

- Patient has not previously been tested with the Guardant360® test for the same primary cancer. For a patient who has been tested previously using Guardant360 for a cancer, that patient may only be test again unless when the patient as a new primary cancer diagnosis. In a patient with previously tested primary cancer, who has evidence of new malignant growth, that growth may be considered to be a different primary cancer if it does not originate from the same cell line or it is physiologically different enough that it responds differently to treatment than the previously tested cancer, **and**
- Patient is untreated for the primary cancer being tested or the patient is not responding to treatment (e.g. progression or new lesions on treatment), **and**
- The patient has decided to seek further cancer treatment with the following conditions:
 - The patient is a candidate for further treatment with a drug that is either FDA approved for that patient's cancer, or has an NCCN 1 or NCCN 2A recommendation for that patient's cancer, **and**
 - The FDA-approved indication for NCCN recommendation is based upon information about the presence or absence of a genetic biomarker tested for in the Guardant360 assay, **and**
- Tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated) or specifically in NSCLC Tissue-based CGP has shown no actionable mutations.

The following test will be covered when the applicable medical criteria are met:

- **MSK-IMPACT – 0048U**

Non-Small Cell Lung Cancer (NSCLC)

For the evaluation of tumor tissue in the following clinical circumstances:

- Newly diagnosed patients with advanced (stage IIIB or IV) NSCLC, who are not treatable by resection or radiation with curative intent, and who are suitable candidates for therapy at the time of testing.
- Previously diagnosed patients with advanced (stage IIIB or IV) NSCLC, who have not responded to at least one systemic therapy, or who have progressed following resection. The patient must be a candidate for treatment at the time of the testing.
- Previously diagnosed patients with advanced (stage IIIB or IV) NSCLC, who have been resistant to at least one targeted therapy, are able to undergo tumor tissue biopsy for testing, and who are suitable candidates for additional treatment at the time of testing.

Metastatic Colorectal Cancer (mCRC)

When the test is performed in a CLIA-certified laboratory qualified to perform high complexity testing, ordered by a treating physician, and the patient has:

- metastatic CRC; and
- is a candidate for intensive chemotherapy with an anti-EGFR biologic agent; and
- has not had prior RAS/BRAF testing (except after initiation of anti-EGFR therapy with evidence of acquired resistance).

Commercial Products

The following test will be covered when the applicable medical criteria are met:

- **Guardant360® CDx – 0242U (Code Effective 4/1/2021. For Dates of Service prior to 4/1/2021, an Unlisted CPT code must be used.)**

Guardant360® CDx test may be considered medically necessary as an alternative to tissue biopsy* when the following criteria is met:

At diagnosis:

- Analysis will be performed on ONLY somatic variants in exons 19 through 21 (eg, exon 19 deletions, L858R, T790M) within the epidermal growth factor receptor (EGFR) gene, with plasma specimens to detect circulating tumor DNA (ctDNA), AND
- The test is used to predict treatment response to an *EGFR* tyrosine kinase inhibitor therapy (eg, erlotinib [Tarceva], gefitinib [Iressa], afatinib [Gilotrif], dacomitinib [Vizimpro], or osimertinib [Tagrisso]) in patients with any of the following:
 - advanced lung adenocarcinoma
 - large cell carcinoma
 - advanced squamous cell non-small-cell lung cancer
 - non-small-cell lung cancer not otherwise specified

OR**With disease progression:**

- Analysis of the *EGFR* T790M resistance variant for targeted therapy with OSIMERTINIB using ctDNA with plasma specimens to detect circulating tumor DNA (ctDNA),
- In patients with any of the following:
 - advanced lung adenocarcinoma
 - large cell carcinoma
 - advanced squamous cell non-small-cell lung cancer
 - non-small-cell lung cancer not otherwise specified when:

*Definition of Alternative to Tissue Biopsy:

Obtaining a new tissue is not feasible, e.g., in those who do not have enough tissue for standard molecular testing using formalin-fixed paraffin-embedded tissue, do not have a biopsy-amenable lesion, or cannot undergo biopsy.

PRIOR AUTHORIZATION**Medicare Advantage Plans**

Prior authorization is required for Medicare Advantage Plans for the following tests:

- Oncomine™ Dx Target Test
- FoundationOne CDx™ (F1CDx)
- Guardant360® CDx
- MSK-IMPACT
- Praxis (TM) Extended RAS Panel
- myChoice® CDx

Commercial Products

Prior authorization is recommended for Commercial Products for the following tests:

- Guardant360® CDx

Medicare Advantage Plans and Commercial Products

There is no specific CPT coding for some of the services referenced in this policy. Therefore, an Unlisted CPT code should be used (see Coding Section for details). All Unlisted genetic testing CPT codes require prior authorization to determine what service is being rendered and if the service is covered or not medically necessary. See the Related Policies section.

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products and is obtained via the online tool for participating providers. See the Related Policies section.

POLICY STATEMENT

Medicare Advantage Plans

The following tests may be considered medically necessary when the medical criteria above are met:

- Oncomine™ Dx Target Test
- FoundationOne CDx™ (F1CDx)
- Guardant360® CDx
- MSK-IMPACT
- Praxis (TM) Extended RAS Panel
- myChoice® CDx

Commercial Products

The following test may be considered medically necessary when the medical criteria above are met:

- Guardant360® CDx

The following tests are not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes:

- Oncomine™ Dx Target Test
- FoundationOne CDx™ (F1CDx)
- MSK-IMPACT
- Praxis (TM) Extended RAS Panel
- myChoice® CDx

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable laboratory and not medically necessary benefits/coverage.

BACKGROUND

Commercial Products

TRADITIONAL THERAPEUTIC APPROACHES TO CANCER

Tumor location, grade, stage, and the patient's underlying physical condition have traditionally been used in clinical oncology to determine the therapeutic approach to a specific cancer, which could include surgical resection, ionizing radiation, systemic chemotherapy, or combinations thereof. Currently, some 100 different types are broadly categorized according to the tissue, organ, or body compartment in which they arise. Most treatment approaches in clinical care were developed and evaluated in studies that recruited subjects and categorized results based on this traditional classification scheme.

This traditional approach to cancer treatment does not reflect the wide diversity of cancer at the molecular level. While treatment by organ type, stage, and grade may demonstrate statistically significant therapeutic efficacy overall, only a subgroup of patients may derive clinically significant benefit. It is unusual for a cancer treatment to be effective for all patients treated in a traditional clinical trial. Spear et al (2001) analyzed the efficacy of major drugs used to treat several important diseases. They reported heterogeneity of therapeutic responses, noting a low rate of 25% for cancer chemotherapeutics, with response rates for most drugs falling in the range of 50% to 75%. The low rate for cancer treatments is indicative of the need for better identification of characteristics associated with treatment response and better targeting of treatment to have higher rates of therapeutic responses.

TARGETED CANCER THERAPY

Much of the variability in clinical response may result from genetic variations. Within each broad type of cancer, there may be a large amount of variability in the genetic underpinnings of the cancer. Targeted cancer treatment refers to the identification of genetic abnormalities present in the cancer of a particular patient, and the use of drugs that target the specific genetic abnormality. The use of genetic markers allows cancers to be

further classified as “pathways” defined at the molecular level. An expanding number of genetic markers have been identified. Dienstmann et al (2013) categorized these findings into 3 classes, which are listed following: (1) genetic markers that have a direct impact on care for the specific cancer of interest, (2) genetic markers that may be biologically important but are not currently actionable, and (3) genetic markers of uncertain importance.

A smaller number of individual genetic markers fall into the first category (ie, have established utility for a particular cancer type). The utility of these markers has been demonstrated by randomized controlled trials that select patients with the marker and report significant improvements in outcomes with targeted therapy compared with standard therapy. Testing for these individual variants with established utility is not covered in this evidence review. In some cases, limited panels may be offered that are specific to one type of cancer (eg, a panel of several markers for NSCLC). This review is also not intended to address the use of cancer-specific panels that include a few variants. Rather, this review addresses expanded panels that test for many potential variants that do not have established efficacy for the specific cancer in question.

When advanced cancers are tested with expanded molecular panels, most patients are found to have at least one potentially pathogenic variant. The number of variants varies widely by types of cancers, different variants included in testing, and different testing methods among the available studies. In a study by Schwaederle et al (2015), 439 patients with diverse cancers were tested with a 236-gene panel. A total of 1813 molecular alterations were identified, and almost all patients (420/439 [96%]) had at least 1 molecular alteration. The median number of alterations per patient was 3, and 85% of patients (372/439) had 2 or more alterations. The most common alterations were in the genes TP53 (44%), KRAS (16%), and PIK3CA (12%) genes.

Some evidence is available on the generalizability of targeted treatment based on a specific variant among cancers that originate from different organs. There are several examples of variant-directed treatment that is effective in one type of cancer but ineffective in another. For example, targeted therapy for epidermal growth factor receptor variants have been successful in non-small-cell lung cancer but not in trials of other cancer types. Treatment with tyrosine kinase inhibitors based on variant testing has been effective for renal cell carcinoma but has not demonstrated effectiveness for other cancer types tested. “Basket” studies, in which tumors of various histologic types that share a common genetic variant are treated with a targeted agent, also have been performed. One such study was published in 2015 by Hyman et al. In this study, 122 patients with BRAF V600 variants in nonmelanoma cancers were treated with vemurafenib. The authors reported that there appeared to be antitumor activity for some but not all cancers, with the most promising results seen for non-small-cell lung cancer, Erdheim-Chester disease, and Langerhans cell histiocytosis.

The following is a list of commercially available expanded cancer molecular panels.

Please note: this is NOT an all-inclusive list.

Test	Manufacturer
FoundationOne®CDx test (F1CDx)	Foundation Medicine
FoundationOne®CDx Heme test	Foundation Medicine
OnkoMatch™	GenPath Diagnostics
GeneTrails® Solid Tumor Panel	Knight Diagnostic Labs

Tumor profiling service	Caris Molecular Intelligence through Caris Life Sciences
SmartGenomics™	PathGroup
Paradigm Cancer Diagnostic (PcDx™) Panel	Paradigm
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT™)	Memorial Sloan Kettering Cancer Center
TruSeq® Amplicon Panel	
TruSight™ Oncology	Illumina
Ion AmpliSeq™ Comprehensive Cancer Panel	
Ion AmpliSeq™ Cancer Hotspot Panel v2	Thermo Fisher Scientific
OmniSeq Comprehensive	OmniSeq
Oncomine DX Target Test	Thermo Fisher Scientific

In 2017, FoundationOne CDx (Foundation Medicine) received premarket approval by the U.S. Food and Drug Administration (FDA) (P170019) as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 2. "Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms."

In 2017, the Oncomine DX Target Test (Life Technologies Corp) received premarket approval by the FDA (P160045) to aid in selecting non-small cell lung cancer patients for treatment with approved targeted therapies.

MSK-IMPACT (Memorial Sloan Kettering) received de novo marketing clearance in 2017 (DEN170058). "The test is intended to provide information on somatic mutations (point mutations and small insertions and deletions) and microsatellite instability for use by qualified health care professionals in accordance with professional guidelines and is not conclusive or prescriptive for labeled use of any specific therapeutic product."

In August 2020, Guardant360® CDx (Guardant Health), a qualitative next generation sequencing-based diagnostic of circulating cell-free DNA in plasma, was approved by the FDA through the premarket approval process (P200010).³ The plasma test is approved as a companion diagnostic for selecting NSCLC patients who have *EGFR* exon 19 deletions, L858R substitution variants, or T790M variants, for treatment with osimertinib. Patients who test negative for the variants detected should be referred for (or "reflexed" to) routine biopsy with tissue testing for *EGFR* variants. Testing for T790M using plasma specimens is most appropriate for consideration in patients for whom a tumor biopsy cannot be obtained, as the efficacy of osimertinib has not been established in T790M plasma-positive, tissue-negative or unknown patient populations.

For individuals who have advanced cancer that is being considered for targeted therapy who receive comprehensive genomic profiling of tumor tissue, the evidence includes a randomized controlled trial, nonrandomized trials, and systematic reviews of these studies. Relevant outcomes are overall survival,

disease-specific survival, test validity, and quality of life. A large number of variants and many types of cancer preclude determination of the clinical validity of the panels as a whole, and clinical utility has not been demonstrated for the use of expanded molecular panels to direct targeted cancer treatment. The 1 published randomized controlled trial (SHIVA trial) that used an expanded panel reported no difference in progression-free survival compared with standard treatment. Additional randomized and nonrandomized trials for drug development, along with systematic reviews of these trials, have compared outcomes in patients who received molecularly targeted treatment with patients who did not. Generally, trials in which therapy was targeted to a gene variant resulted in improved response rates, progression-free survival, and overall survival compared to patients in trials who did not receive targeted therapy. A major limitation in the relevance of these studies for comprehensive genomic profiling is that treatment in these trials was guided both by the tissue source and the molecular target for drug development, rather than being matched solely by the molecular marker (ie, basket trials). As a result, these types of studies do not provide evidence of the benefit of broad molecular profiling compared to more limited genetic assessments based on known tumor-specific variants. Basket trials that randomize patients with various tumor types to a strategy of comprehensive genomic profiling followed by targeted treatment are needed, and several are ongoing. The evidence is insufficient to determine the effects of the technology on health outcomes.

Medicare Advantage Plans

NGS for Somatic (Acquired) and Germline (Inherited) Cancer

Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, *in vitro* companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variations as a laboratory diagnostic test, such as when used as a companion *in vitro* diagnostic test.

Patients with cancer can have recurrent, relapsed, refractory, metastatic, and/or advanced stages III or IV of cancer. Clinical studies show that genetic variations in a patient's cancer can, in concert with clinical factors, predict how each individual responds to specific treatments.

In application, a report of results of a diagnostic laboratory test using NGS (i.e., information on the cancer's genetic variations) can contribute to predicting a patient's response to a given drug: good, bad, or none at all. Applications of NGS to predict a patient's response to treatment occurs ideally prior to initiation of such treatment.

The Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a CLIA-certified laboratory, when ordered by a treating physician and when the criteria above are met.

The evidence for cancers of the breast and ovary suggests that the use of NGS can identify germline mutations which will lead to better treatment and health outcomes for patients with inherited cancers of the breast and ovary. The evidence for cancer of the breast and ovary indicates that NGS as a diagnostic tool can identify the germline mutations most likely to be targeted by a treatment regimen tailored to certain germline mutation. It is likely that the identification of such tailored treatment regimens in the clinical management of inherited cancers of the breast and ovary diagnosed by NGS will improve health outcomes of Medicare beneficiaries. Use of NGS as a diagnostic test has utility for patients in the discovery of new targeted therapies for inherited cancers and in the physician management of inherited cancers of the breast and ovary in Medicare beneficiaries.

Non-Small Cell Lung Cancer (NSCLC)

In total, there are over 40 single nucleotide or small insertion/deletion variants occurring at numerous specific loci in ten genes. These variants represent potential therapeutic targets and, as therapeutic agents aimed at these targets are proven safe and effective and meet Medicare coverage guidelines, additional genes

may be added to National Comprehensive Cancer Network (NCCN) Category 1 or 2A Recommended Therapeutic Options. In addition, gene fusions can involve five different genes, and amplification is the significant recognized alteration in at least one gene.

Metastatic Colorectal Cancer (mCRC)

The genetic factors with strong evidence for clinical decision-making (both prognostic and predictive of chemotherapy efficacy) are BRAF and RAS mutations along with MMR status. Guidelines from NCCN, the European Society for Medical Oncology (ESMO), as well as a combined guideline from the American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and ASCO consider certain molecular genetic biomarkers necessary for diagnosis and management of mCRC. Testing is not necessary for mCRC patients being considered for palliative or hospice care only. Re-testing may be indicated after initiation of anti-EGFR treatment if resistance develops.

CODING

The following CPT codes may be considered medically necessary for Medicare Advantage Plans when the medical criteria above are met and are not medically necessary for Commercial Products:

This code can be used for OncoPrint™ Dx Target Test:

0022U Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider

This code can be used for FoundationOne CDx™ (F1CDx):

0037U Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden

This code can be used for MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets):

0048U Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)

This code can be used for Praxis (™) Extended RAS Panel:

0111U Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue

This code can be used for myChoice® CDx:

0172U Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score

The following CPT code may be considered medically necessary for Medicare Advantage Plans and Commercial Products when the medical criteria above are met:

This code can be used for Guardant360® CDx:

0242U Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements (New Code Effective 4/1/2021. For Dates of Service prior to 4/1/2021, an Unlisted CPT code must be used.)

Most available expanded cancer molecular panels have not been assigned CPT codes and should be filed with an appropriate genetic testing Unlisted CPT code.

RELATED POLICIES

Medicare Advantage Plans National and Local Coverage Determinations
Genetic Testing Services
Proprietary Laboratory Analyses (PLA)

PUBLISHED

Provider Update, June 2021
Provider Update, February 2021
Provider Update, July 2019
Provider Update, June 2018

REFERENCES

1. Centers for Medicare and Medicaid Services. National Covered Determination (NCD) for Next Generation Sequencing (NGS) (90.2)
2. Centers for Medicare and Medicaid Services. Local Covered Determination (LCD): Genomic Sequence Analysis in the Treatment of Solid Organ Neoplasms (L37810)
3. Noridian Healthcare Solutions, Jurisdiction E, Article Detail: Guardant360 and Prospera. Article Detail - JE Part B - Noridian (noridianmedicare.com)
4. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. *Trends Mol Med*. May 2001; 7(5): 201-4. PMID 11325631
5. Dienstmann R, Rodon J, Barretina J, et al. Genomic medicine frontier in human solid tumors: prospects and challenges. *J Clin Oncol*. May 20 2013; 31(15): 1874-84. PMID 23589551
6. Drilon A, Wang L, Arcila ME, et al. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. *Clin Cancer Res*. Aug 15 2015; 21(16): 3631-9. PMID 25567908
7. Johnson DB, Dahlman KH, Knol J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. *Oncologist*. Jun 2014; 19(6): 616-22. PMID 24797823
8. Schwaederle M, Daniels GA, Piccioni DE, et al. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. *Mol Cancer Ther*. Jun 2015; 14(6): 1488-94. PMID 25852059
9. O'Brien CP, Taylor SE, O'Leary JJ, et al. Molecular testing in oncology: problems, pitfalls and progress. *Lung Cancer*. Mar 2014; 83(3): 309-15. PMID 24472389
10. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med*. Aug 20 2015; 373(8): 726-36. PMID 26287849
11. Le Tourneau C, Kamal M, Tredan O, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. *Target Oncol*. Dec 2012; 7(4): 253-65. PMID 23161020
12. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol*. Oct 2015; 16(13): 1324-34. PMID 26342236
13. Belin L, Kamal M, Mauborgne C, et al. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. *Ann Oncol*. Mar 01 2017; 28(3): 590-596. PMID 27993804
14. Schwaederle M, Zhao M, Lee JJ, et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. *J Clin Oncol*. Nov 10 2015; 33(32): 3817-25. PMID 26304871
15. Jardim DL, Fontes Jardim DL, Schwaederle M, et al. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. *J Natl Cancer Inst*. Nov 2015; 107(11). PMID 26378224
16. Zimmer K, Kocher F, Spizzo G, et al. Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. *Comput Struct Biotechnol J*. 2019; 17: 447-453. PMID 31007870

17. Wheler JJ, Janku F, Naing A, et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. *Cancer Res.* Jul 01 2016; 76(13): 3690-701. PMID 27197177
18. Tsimberidou AM, Hong DS, Ye Y, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. *JCO Precis Oncol.* 2017; 2017. PMID 29082359
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 6.2020 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed September 4, 2020.
20. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 4.2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed September 6, 2020.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 8.2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed September 10, 2020.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 4.2020. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed September 7, 2020.
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed September 11, 2020.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed September 5, 2020.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 3.2020. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed September 8, 2020.
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 4.2020. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed September 2, 2020
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 6.2020. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 3, 2020.
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft-Tissue Sarcoma. Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed September 13, 2020.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1:2020. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed September 12, 2020.
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 1, 2020.
31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 5.2020. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed September 9, 2020.
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Volume 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed September 14, 2020.
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 3.2020. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed September 15, 2020.
34. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the

College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. Mar 2018; 13(3): 323-358. PMID 29396253

35. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. Mar 20 2018; 36(9): 911-919. PMID 29401004

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

